FDA Approves Celltrion Aflibercept Biosimilar: Eydenzelt

European Data Confirm Real-World Benefits of Adalimumab Biosimilars

June 11th 2025

By Skylar Jeremias

New research highlights the efficacy and high patient satisfaction of adalimumab biosimilars in treating inflammatory diseases.

Sandoz, STADA, and Samsung Bioepis Report Strong Earnings From Biosimilars

June 10th 2025

By Skylar Jeremias

Leading biosimilar companies Sandoz, STADA Arzneimittel, and Samsung Bioepis report impressive Q1 2025 growth, driven by strong denosumab biosimilars and expanding portfolios.

Boosting Biosimilar Use in Osteoporosis: Why HCP Education Matters

June 9th 2025

By Skylar Jeremias

The biosimilar industry faces awareness challenges among health care professionals (HCPs), which must be addressed to increase cost savings and patient access to treatments.

5 Key Takeaways From the "Escaping the Void" Video Podcast

June 8th 2025

By Skylar Jeremias

Indian Study Finds Comparable Outcomes Between Reference, Biosimilar Bevacizumab in CRC

June 7th 2025

By Deana Ferreri, PhD

Real-world study reveals comparable effectiveness of bevacizumab biosimilars and Avastin in metastatic colorectal cancer (CRC), boosting clinician confidence.

The Top 5 Biosimilar Articles for the Week of June 2

June 6th 2025

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of June 2, 2025.

Infliximab Biosimilar Switch Due to Flare Risk: Monitoring Patients Is Crucial for Pharmacists

June 5th 2025

By Cameron Santoro

Switching from reference infliximab to biosimilars (infliximab-abda and infliximab-dyyb) for rheumatic diseases may lead to treatment delays and a higher risk of disease flares, particularly when the switch is mandated by insurance.

Billions in Health Care Savings Realized Through Early Generic, Biosimilar Settlements

June 4th 2025

By Skylar Jeremias

Patent settlements accelerate the entry of generics and biosimilars, saving the health care system $422.9 billion and enhancing drug accessibility.

FDA-Approved SB16 Biosimilar Demonstrates Equivalence to Prolia

June 3rd 2025

By Skylar Jeremias

New research confirms denosumab biosimilar SB16 matches Prolia in efficacy, offering a cost-effective treatment option for postmenopausal osteoporosis.

Wyost and Jubbonti Launch as First Denosumab Biosimilars in the US

June 2nd 2025

By Skylar Jeremias

Denosumab biosimilars Wyost and Jubbonti launch in the US, enhancing access to affordable treatments for osteoporosis and cancer-related skeletal events.